Tris Pharma receives USFDA approval for ONYDA XR, a liquid non-stimulant ADHD medication EP News Bureau May 30, 2024 ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in…
